NATHAN NGO: Open Payments
NPI 1043935380 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,292 in 105 payments from 16 companies in 2025. Trend: 2023 $233 · 2024 $1,075 · 2025 $3,292
Food & beverage: $3,292
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 7 | $592 |
| E.R. Squibb & Sons, L.L.C. | 14 | $555 |
| Otsuka America Pharmaceutical, Inc. | 18 | $445 |
| Teva Pharmaceuticals USA, Inc. | 15 | $379 |
| Neurocrine BioSciences, Inc. | 9 | $280 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $238 |
| Vanda Pharmaceuticals Inc. | 8 | $222 |
| ABBVIE INC. | 9 | $178 |
| ACADIA Pharmaceuticals Inc | 3 | $138 |
| Lundbeck LLC | 4 | $103 |
Products named: COBENFY, INVEGA SUSTENNA, REXULTI, INGREZZA, UZEDY, CAPLYTA, FANAPT, VRAYLAR.
Industry payments across CA — which companies pay providers there.
